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kidney disease. A combined analysis from the PLANET 
studies8 showed that individuals randomly assigned to 
atorvastatin not only had lower levels of proteinuria at 
the end of the 12-month study but also had signiﬁ cantly 
slower decline in kidney function. Findings of other 
studies have suggested that at least some statins might 
have beneﬁ cial eﬀ ects on kidney function.8,9 Although 
eﬀ ects on kidney function were not assessed in the CTT 
Collaboration’s current meta-analysis, it is an important 
topic worthy of more detailed analysis, and ideally 
suited to the CTT Collaboration’s datasets, and perhaps 
studies of PCSK9 inhibitors. 
Although the results from this CTT Collaboration 
meta-analysis provide clear evidence of the role of 
statins in chronic kidney disease, they raise further 
questions about the eﬀ ects of lipid-lowering in 
advanced disease and highlight the importance of new 
trials with highly eﬀ ective agents in this population. 
By deﬁ ning what we still do not know, this analysis 
will hopefully encourage further studies that improve 
outcomes for this high-risk patient group. 
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Cardiac natriuretic peptides in plasma: from prediction to 
precision medicine
In The Lancet Diabetes and Endocrinology, the Natriuretic 
Peptides Study Collaboration1 show plasma measurement 
of the cardiac hormone N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) to be predictive not only of 
coming coronary heart disease, but also future stroke 
in individuals without known cardiovascular disease at 
the time of measurement (risk ratio for combination 
of coronary heart disease and stroke 1·76 [95% CI 
1·56–1·98]). The individual-participant-data meta-
analysis included 40 prospective cohorts comprising 
over 95 000 individuals and is thus the largest study 
of its kind of NT-proBNP measurement in plasma. 
The authors conclude that addition of NT-proBNP 
measurements to conventional risk assessment in people 
without cardiovascular disease might improve accuracy 
in cardiovascular and stroke risk prediction, which means 
that some individuals at increased risk might be identiﬁ ed 
for possible therapeutic or lifestyle interventions.
Measurement of cardiac natriuretic hormones and 
their precursors in plasma has mostly been a matter of 
congestive heart failure. Today, plasma measurement is 
included in all high-income country guidelines for heart 
failure assessment, for which the natriuretic hormones 
and prohormones best serve to rule out the presence 
of congestive heart failure. Strikingly, this use basically 
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peptide concentration measurement in plasma published 
in 1986 by Burnett Jr and colleagues.2 Since then, plasma 
measurement has been complicated by the fact that the 
endocrine heart seems much more endocrine than ﬁ rst 
assumed, meaning that post-translational processing 
of both proatrial natriuretic peptide and NT-proBNP 
results in the existence of multiple peptide species, rather 
than just one active hormone (here B-type natriuretic 
peptide) and one inert fragment (here NT-proBNP).3 This 
ﬁ nding, in turn, means that measurement of peptides in 
plasma strongly relies on the biochemical method used; 
the Natriuretic Peptides Study Collaboration1 quantiﬁ ed 
NT-proBNP calibrated against non-glycosylated 
NT-proBNP 1–76. In terms of general mechanism, 
whether or not glycosylated NT-proBNP concentration 
assessment as well as assessment for the other cardiac 
peptides would provide the same or even additional 
information, as suggested by other studies at least in 
heart failure assessment, would be valuable to see.4
New markers of risk always have a way to go before 
they might or might not be implemented in clinical 
practice. One could argue that the true challenge for 
any given risk marker is whether or not it can progress 
from mere prediction without obvious intervention to 
precision medicine with deﬁ ned therapeutic treatment 
or lifestyle interventions for the individual. What is 
the general practitioner going to do with a patient 
for whom an incidental measurement of plasma 
NT-proBNP concentration is 137 pmol/L? From the 
study by the Natriuretic Peptides Study Collaboration,1 
that particular patient is at markedly increased risk 
of cardiovascular disease and stroke, yet the practical 
consequence of this information is not straightforward. 
This is particularly true in view of the fact that several 
therapeutic interventions come with their own risk 
proﬁ les (eg, medicine for stroke prevention).
Prediction studies might hold more information than 
just the overall, simpliﬁ ed sum of risk. In the study by the 
Natriuretic Peptides Study Collaboration1, for instance, a 
particular group of individuals are highlighted in whom 
risk assessment would be justiﬁ ed on the basis of other 
risk factors. The authors follow this line to some extent, 
showing that the risk information garnered from 
NT-proBNP concentration measurements seems greater 
in older than in younger individuals and in patients with 
diabetes than in those without. The endocrine heart 
still remains a subject of science as cardiac production 
of natriuretic peptides might be aﬀ ected by diabetes.5 
Likewise, glucagon-like peptide 1 analogues might 
aﬀ ect secretion of natriuretic peptides.6 In essence, 
NT-proBNP concentration in plasma could therefore 
simply reﬂ ect the severity of the diabetes and hence 
its concurrent treatment status. Studies of natriuretic 
peptide measurement in patients with diabetes stratiﬁ ed 
according to disease severity and treatment modules are 
certainly needed.
Yet, the study by the Natriuretic Peptides 
Study Collaboration1 causes consideration of the 
possible future place for NT-proBNP concentration 
measurement in precision medicine. Clearly, identiﬁ -
cation of individuals before disease onset is a growing 
ﬁ eld, one that has the potential to truly improve general 
health and quality of life. However, biomarkers should 
undergo extreme scrutiny and critical assessment 
before treatment is introduced on the basis of such 
surrogate measures of risk. Basic science should be 
pursued alongside prospective intervention studies 
assessing the use of such biomarkers. Essentially, the key 
question is how the endocrine heart can foresee coming 
cardiovascular disease and stroke. New therapeutic 
interventions might be possible and thus biomarkers 
might be able to help not only identify risk of coming 
disease but also allow for the best intervention for 
that particular risk in that particular person.7 Perhaps 
then prediction assessment can be moved to precision 
medicine, with the worthy outcome of improvement of 
human quality and length of life.
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Splitting atoms: the Endocrine Society guideline for the 
management of primary aldosteronism
On the 60th anniversary of Jerome Conn’s ﬁ rst published 
description of his eponymous syndrome,1 the Endocrine 
Society should be congratulated for its timely and 
thorough revision2 of its 2008 guideline for clinicians for 
detection and management of primary aldosteronism, 
which adds several new recommendations (panel).
Emphasis on the public health aspect is ﬁ tting. Long 
before eponymous syndromes, or their splitting oﬀ 
from common conditions, were rebranded as stratiﬁ ed 
medicine, Conn predicted that primary aldosteronism 
would be found to “masquerade” as essential hyper-
tension in perhaps 20% of patients.3 The proof that 
this prediction is an underestimate in some patient 
groups (particularly those with resistant hypertension) 
and is perhaps only twice the true prevalence in 
unselected patients, had to await modern imaging and 
biochemistry.4,5 These techniques brought recognition 
that primary aldosteronism itself is split roughly half and 
half between potentially curable unilateral aldosterone-
producing adenomas and bilateral adreno cortical 
hyperplasia, and that these diseases could be diagnosed 
in the absence of either hypokalaemia, elevated plasma 
aldosterone concentration, or un ambiguous adenoma on 
CT scanning. Since 2008, new molecular stratiﬁ cations 
of primary aldosteronism have been discovered, but 
whether these techniques can help to address the 
pressing public health challenge is unknown. Despite 
20 years of advances in diagnosis and publications of 
double-ﬁ gure prevalences, these prevalences appear to 
remain a well-kept secret outside of specialist circles. 
Hospital episode statistics in England consistently show 
that only about 250 people have an adrenalectomy each 
year for unilateral primary aldosteronism compared 
with an expected incidence, if all were diagnosed and 
operated, of 5000–10 000 people per year.6
Some of the explanation for the level of under-
diagnosis is implicit from the nature of the guideline. 
This guideline is explicitly a comprehensive manual 
for the specialist, not a simple guide (which is now 
promised), which will encourage the generalist. 
Moreover, because aldosterone-producing adenomas 
seem to always be benign and rarely grow, because 
the (retrospectively characterised) risks from primary 
aldosteronism are in the future, whereas surgical 
morbidity is now,7 and because long-term outcomes 
from adrenalectomy are largely unstudied and 
unknown, the complexity of the diagnostic inter vention 
can appear inversely proportional to the size of the 
proven beneﬁ ts of intervention. Multiple precautions 
are recommended before a blood sample should be sent 
for diagnosis, and 20 diﬀ erent thresholds are listed for 
the aldosterone-to-renin ratio. The guideline recognises 
the limitations and diﬃ  culties of aldosterone-to-renin 
ratio measurement and subsequent conﬁ rmatory 
tests, so the barrier to CT imaging of the adrenals 
has been lowered—a little. The probability of an 
aldosterone-producing adenoma existing is increased 
once an adenoma is detected by CT, and an anatomical 
diagnosis leading to possible surgery justiﬁ es extensive 
investigation. The beneﬁ ts and risks of intervention 
and the patient’s own preferences are diﬃ  cult to discuss 
before imaging has been done. 
The conﬂ ict between public health and individual 
patient considerations is tackled by retention of the 
Panel: New features in the revised Endocrine Society 
guideline2
Recognition of primary aldosteronism as a major public 
health issue because of its prevalence and associated 
cardiovascular and renal damage
Broader indications for screening compared with the previous 
(2008) guideline (now including a blood pressure of 
>150/100 mm Hg on no therapy)
Explicit recommendation for primary care physicians to refer 
patients with suspected primary aldosteronism to specialist 
centres
Endorsement of abbreviated (no saline suppression) 
investigations in patients with spontaneous hypokalaemia 
and very low renin and very high aldosterone concentrations
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